Klebsiella oxytoca
Report Name: 2003 Pedi Klebsiella oxytoca
Query Selection Criteria:
Report Start Date: 01/01/2003 (MM/DD/YYYY)
Report End Date: 12/31/2003 (MM/DD/YYYY)
Organism: Klebsiella oxytoca
Drug: Amikacin;Ampicillin;Cefazolin;Cefepime;Cefotaxime;Ceftazidime;Ce
ftriaxone;Ciprofloxacin;Colistin;Gentamicin;Imipenem;Nitrofurantoi
n;Piperacillin;Piperacillin/tazobactam;Tobramycin;Trimeth/sulfa
Breakpoint: NCCLS
Patient Type: Inpatient;Inpatient - ICU;Outpatient
Patient Age: greater than or equal to 0 AND less than or equal to 18
Institution: T84 University of CA at San Francisco - Parnassus
Street-ALL;T84 Mt. Zion Medical Center - Divisedero Street
Trending: None
Dataset: Institution
Chosen Country: United States
Organism Klebsiella oxytoca S S I I R R
Drug Total N % N % N %
Amikacin 13 13 100.0 % 0 0.0 % 0 0.0 %
Ampicillin 13 0 0.0 % 1 7.7 % 12 92.3 %
Cefazolin 13 8 61.5 % 3 23.1 % 2 15.4 %
Cefepime 13 13 100.0 % 0 0.0 % 0 0.0 %
Cefotaxime 13 13 100.0 % 0 0.0 % 0 0.0 %
Ceftazidime 13 13 100.0 % 0 0.0 % 0 0.0 %
Ceftriaxone 13 13 100.0 % 0 0.0 % 0 0.0 %
Ciprofloxacin 13 13 100.0 % 0 0.0 % 0 0.0 %
Gentamicin 13 13 100.0 % 0 0.0 % 0 0.0 %
Imipenem 13 13 100.0 % 0 0.0 % 0 0.0 %
Nitrofurantoin 7 7 100.0 % 0 0.0 % 0 0.0 %
Piperacillin 6 6 100.0 % 0 0.0 % 0 0.0 %
Piperacillin/tazobactam 13 13 100.0 % 0 0.0 % 0 0.0 %
Tobramycin 13 13 100.0 % 0 0.0 % 0 0.0 %
Trimeth/sulfa 13 12 92.3 % 0 0.0 % 1 7.7 %
For agents with >25% of strains tested:
Plain=<60% activity